Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|November 13, 2007
Growth hormone delivery system approved
New delivery device approved for somatropin (Saizen).
Advertisement
EMD Serono has received an FDA approval for Easypod, a novel delivery system for the administration of somatropin ([rDNA origin] Saizen). The device features preset dosing, which eliminates the need for patients to set their dose each day and also tracks the number of doses administered. Easypod is intended for use with Saizen Click.Easy cartridges. Saizen is indicated for the treatment of children and adults with growth hormone deficiency.
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
A high-dose flu vaccine lowered flu- and pneumonia-related hospital stays in patients with chronic lung disease, reinforcing flu and pneumococcal vaccinations.
In a review of records assessing patients with type 2 diabetes, researchers provide a comprehensive detail of strategies leading to diabetes remission though gaps persist.
A guide built from conversations with pharmacists on social media and independent pharmacy owners.
Exploring the effects of weight-loss and GLP-1 therapies, researchers determine the specific metabolic determinants that lead to patients’ weight reduction.
Observed by APhA and ASHP since 2023, bipartisan support has garnered to give pharmacy workforce suicide awareness its own federally recognized day.
Atogepant reduced migraine days during the perimenstrual period, positioning the medication as a potential first treatment option for the condition.
Chad Worz, PharmD, BCGP, FASCP, discusses the Main Street Pharmacy Access Act, a revolutionary pharmacy-focused bill moving through Congress.
Advertisement
Advertisement
Trending on Drug Topics
1
COVID-19 Vaccine Hesitancy in 2026: How Attitudes Have Shifted
2
GLP-1 Therapy Must Prioritize Metabolic Quality Over Weight Loss
3
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
4
Generic Drug Costs Burdening Patients as Much as Brand Name Options
5